Effects of galantamine in alzheimer's disease: Double-blind withdrawal studies evaluating sustained versus interrupted treatment

Current Alzheimer Research

Volumn 8, Issue 7, 2011, Pages 771-780

  Gaudig, M ^a   Richarz, U ^b   Han, J ^c   van Baelen, B ^d   Schauble B ^e  

^a JANSSEN CILAG GMBH   (Germany)

^b Cilag AG   (Switzerland)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d SGS Medisearch International NV   (Belgium)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Alzheimer's disease; Clinical trial; Dementia; Galantamine; Randomized withdrawal; Treatment

Indexed keywords

GALANTAMINE; PLACEBO;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; COGNITION; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FALLING; FEMALE; HEADACHE; HUMAN; INJURY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREMOR; URINARY TRACT INFECTION; VOMITING;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 80054059456     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511797633205     Document Type: Article

References (31)

1. Heese K, Akatsu H. Alzheimer's disease--an interactive perspective. Curr Alzheimer Res 3: 109-21 (2006).
2. Muo R, Schindler A, Vernero I, Schindler O, Ferrario E, Frisoni GB. Alzheimer's disease-associated disability: an ICF approach. Disabil Rehabil 27: 1405-13 (2005).
3. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-14 (1982).
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev: CD005593 (2006).
5. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 11 Suppl 1: 11-8 (2000).
6. Razay G, Wilcock GK. Galantamine in Alzheimer's disease. Expert Rev Neurother 8: 9-17 (2008).
7. Melo JB, Sousa C, Garcao P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 29: 455-64 (2009).
8. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 16: 852-7 (2001).
9. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 71: 589-95 (2001).
10. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261-8 (2000).
11. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54: 2269-76 (2000).
12. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 321: 1445-9 (2000).
13. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20: 120-32 (2005).
14. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebocontrolled, double-blind trial. Lancet Neurol 8: 39-47 (2009).
15. Kavanaugh S, Gaudig M, Van Baelen B, Adami M, Motlagh P, Delgado A, et al. Behavioral symptoms, care giver distress and their response to galantamine treatment in patients with mild to moderate Alzheimer's disease: a pooled analysis Poster presented at the 14th Congress of the European Federation of Neurological Societies (EFNS), September 2010:
16. Bullock R, Erkinjuntti T, Lilienfeld S. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 17: 29-34 (2004).
17. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 11: 734-41 (2004).
18. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in pa tients with probable vascular dementia and mixed dementia. Clin Ther 25: 1765-82 (2003).
19. Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 15: 79-87 (2003).
20. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 61: 252-6 (2004).
21. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 12: 473-82 (2004).
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
23. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 61: 694-9 (2007).
24. National Collaborating Centre for Mental Health commissoned by the National Instiute for Health and Clinical Excellence. National Clinical Practice Guideline Number 72. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. London: The British Psychological Society and The Royal College of Psychiatrists (2009).
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-64 (1984).
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-98 (1975).
27. Reisberg B, Ferris SH, ed. CIBIC-Plus Interview Guide: East Hanover, NJ: Sandoz Pharmaceuticals Corporation, (1994).
28. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 24: 479-88 (2009).
29. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease London: National Institute for Health and Clinical Excellence (2009).
30. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 11. March 2011 London: National Institute for Health and Clinical Excellence (2011).
31. Kavanagh S, Howe I, Brashear HR, Wang D, Baelen BV, Todd M, et al. Long-term response to galantamine in relation to short-term efficacy data: Pooled analysis in patients with mild to moderate Alzheimer's disease. Curr Alzheimer Res Jan 11 [Epub ahead of print] (2011).